Perioperaciina Medicina en-US <p><a href="" rel="license"><img src="" alt="Creative Commons License"></a><br>This work is licensed under a <a href="" rel="license">Creative Commons Attribution 4.0 International License</a></p> (Oleksandr Marchuk) (Viktor Vitkovskyi) Tue, 02 Nov 2021 00:00:00 +0200 OJS 60 The use of Decasan in the local treatment of chronic inflammatory diseases of the tonsils <p>The local sanitation in 40 patients with recurrent tonsillitis was carried out, using Decasan for washing of the lacunae of the palatine tonsils. Clinical observations and bacteriological studies have shown greater efficacy of Decasan in relation to the main pathogens of the tonsillar lacunae, compared to antibiotic solutions traditionally used for washing. Decasan is a highly effective and safe antiseptic for local treatment of patients with chronic inflammatory diseases of the tonsils, contributing to the restoration of local biocenosis, which is confirmed by an increase in the plaiting of normal microflora from the surface of the tonsillar lacunae.</p> B Bill, A Kushnir Copyright (c) 2021 Wed, 24 Nov 2021 00:00:00 +0200 Rheosorbilact in complex intensive therapy of burn toxemia <p>Background.&nbsp; Thermal injuries primarily cause coagulation necrosis and cell death with vascular thrombosis in the areas of the deepest lesion.<br>Objective.&nbsp; To study the effectiveness of rheosorbilact in infusion therapy during the period of burn toxemia.<br>Materials&nbsp;and&nbsp;Methods.&nbsp;The results of monitoring the daily volume of the injected fluid, infusion therapy and renal excretory activity of 25 patients admitted to the Department of Combustiology of Republican Research Center of Emergency Medicine due to burn injury were studied.<br>Results. The average daily volume of infusion therapy in group 1, FI – 119.4 ± 38.4 units at the age of 27.3 ± 5.6 years, was 76 ± 7 ml/kg per day, in group 2 (50.7 ± 7.1 years), FI – 92.5 ± 20.8 units, the introduction of 64 ± 9 ml/kg was effective, in group 3 (71.3 ± 7.0 years), FI – 86.7 ± 12.8 units, the introduction of an average of 48 ± 11 ml/kg per day was sufficient. In the nonlinear nature of changes in intravenous infusion, 4–5-day periods can be noted, probably due to the current factors that determined the need to increase or decrease infusion therapy. The introduction of rheosorbilact in a volume of 10 ml/kg per day increased the hourly renal excretory activity in all patients during the period of toxemia. The diuretic effect was more pronounced in patients of group 1, which corresponded to a greater volume of water load and the severity of burn injury.<br>Conclusions.&nbsp;The introduction of rheosorbilact in a volume of 10 ml/kg per day increased the hourly renal excretory activity in all patients during the period of toxemia.</p> G Khamraeva, Kh Mukhitdinova, G Alauatdinova Copyright (c) 2021 Wed, 24 Nov 2021 00:00:00 +0200 The effectiveness of Dekasan for prevention of postoperative complications after major bone surgeries <p>Antiseptic drug “Decasan” due to its bactericidal, fungicidal, viricidal and sporicidal action is a highly effective medicine for the prevention of postoperative complications in an orthopedic and trauma hospital. Its use can significantly reduce the frequency of complications, and thus reduces the need for systemic antibiotics and slows down the develop-ment of antibiotic resistance.</p> A Kalashnikov, O Kalashnikov, Yu Stavinskiy, Yu Litun, Yu Khodakovsky Copyright (c) 2021 Wed, 24 Nov 2021 00:00:00 +0200 Effect of short-acting b--blockers on heart rate and blood pressure in patients with acute coronary syndrome during percutaneous and coronary intervention <p><strong>Background.</strong> The use of b- blockers in acute coronary syndrome (ACS) is recommended for all patients, who has not contraindications. The study of the effects of esmolol during percutaneous coronary intervention (PCI) remains relevant. <br><strong>Objective.</strong> To evaluate the features of the effect of esmolol (Biblock, “YURiA-PHARM”) on heart rate and blood pressure in patients with ACS during PCI.<br><strong>Materials&nbsp;and&nbsp;methods.</strong>&nbsp;The study included 30 patients, 15 men and 15 women, who were hospitalized in a specialized cardiology department with ACS with elevation of the ST segment. All patients underwent a general clinical examination, ECG recording in 12 leads, PCI according to the standard protocol with ECG and blood pressure monitoring. All patients were given infusion of esmolol before the standard therapy. The level of heart rate reduction, systolic blood pressure (SBP), diastolic blood pressure (DBP), the correlation of heart rate reduction during esmolol infusion with the clinical and functional parameters of patients and the degree of coronary artery (CA) damage were analyzed.<br><strong>Results.&nbsp;</strong>Decreased heart rate and blood pressure during infusion of esmolol in all patients. Before the infusion, the heart rate av-eraged (109.8 ± 4.0) beats per minute. After the infusion – (92.8 ± 3.2) beats per minute, (p &lt; 0.001) with an average duration of infusion (18.2 ± 2.3) minutes. The decrease in SBP levels during infusion occurred on average by (22.8 ± 2.5) mm Hg, DBP – by (16.0 ± 2.1) mm Hg, no patient had hypotension. According to the results of correlation analysis, it was found that the decrease in heart rate with the use of esmolol has a correlation with the average age of patients (r = -0.47, p = 0.0012), with the presence of multivascular coronary artery disease (r = -0.38, p = 0.002). Weaker negative correlation was found with the initial level of SBP (r = -0.28, p = 0.015), the presence of a history of myocardial infarction (r = -0.27, p = 0.005), the presence of signs of left ventricular hypertrophy (LVH) on the ECG (r = -0.22, p = 0.008), and a history of arterial hypertension that was not treated according to current recommendations (r = -0.21, p = 0.032).<br><strong>Conclusions.</strong> The use of esmolol solution in patients with ACS who have supraventricular tachycardia and elevated blood pressure during PCI can improve control of heart rate, SBP and DBP, a significant decrease is observed after 10 minutes of dose titration. Careful titration of esmolol solution and monitoring of ECG and blood pressure revealed no side effects, including bradycardia and hypotension, which indicates a high safety profile of the drug.</p> L Rasputina, D Didenko, A Solomonchyk Copyright (c) 2021 Wed, 24 Nov 2021 00:00:00 +0200 Coronary revascularization in a patient with cirrhosis and renal failure. Coronary artery bypass grafting in a patient with hepatic cirrhosis and end stage renal disease <p>Surgery in a patient with hepatic cirrhosis entails risk of complications and of death. Association of end stage renal disease (ESRD) along with cirrhosis further increases perioperative risk of morbidity and mortality. There are no reports in the literature of patients with liver cirrhosis and ESRD having undergone cardiac surgery. We present a report of a successfully operated case of ESRD with compensated hepatic cirrhosis posted for coronary artery bypass grafting.</p> Wali Murugesh Copyright (c) 2021 Wed, 24 Nov 2021 00:00:00 +0200 The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia <p>The article presents the results of domestic and international studies of the use of the fourth-generation fluoroquinolone moxifloxacin in the treatment of commu-nity-acquired pneumonia and pneumonia caused by SARS-CoV-2. Analysis of the clinical use of moxifloxacin in the treatment of complications of the respiratory tract infec-tions indicates its high efficiency and bioavailability, a low risk of resistance, which makes it possible to recommend it for widespread use in the work of a practicing doctor. Ge-neric drug Maxicin (Yuria-Pharm), available as a 20 mg/ml concentrate in a 20 ml vial, can significantly reduce the cost of treatment and optimize infusion therapy by choosing both volume and solvent.</p> Dmytro Dmytriiev, Oleksandr Nazarchuk, Yuliana Babina Copyright (c) 2021 Wed, 24 Nov 2021 00:00:00 +0200 The use of hyaluronic acid preparations for the treatment of osteoarthritis of the major joints <p>The authors of the article analyzed the experience of domestic and foreign experts in the effectiveness of the use of HA preparations in the treatment of osteoarthritis of major joints. <br>Background&nbsp; and&nbsp; Objective. To analyze the literature sources in order to determine the effectiveness of the use of HA preparations in the treatment of osteoarthritis of major ligaments. <br>Materials&nbsp;and&nbsp;methods. Articles in specialized scientific journals and collections, Internet resource.<br>Results. The analysis of literature sources determined the important role of HA preparations in the supplying and functioning of the articular cartilage. Researchers are inclined to believe that the ideal HA preparation should be as close as possible to the physiological HA of the synovial fluid of the joint. The developed domestic drug Artro-Patch fully corresponds to these parameters. <br>Conclusions. The use of modern injectable HA preparations is advisable at stages 1–3 of OA. Anti-inflammatory effect of HA preparations makes it possible to reduce the dose and time of administration of non-steroidal anti-inflammatory drugs and, as a consequence, reduce the risk of developing many adverse side effects of NSAIDs. The high level of safety of HA preparations, the absence of serious side effects during their long-term use determine their widespread use in the clinical practice of modern orthopedists.</p> O Kalashnikov, O Sulyma, T Osadchuk, V Zayets, T Nizalov, R Kozak, P Chernyak Copyright (c) 2021 Wed, 24 Nov 2021 00:00:00 +0200